1Cesarone MR, Belcaro G, Nicolaides AN, et al. (1997) Epidemiology and costs of venous diseases in central Italy. The San Valentino Venous Disease project. Angiology 48: 593-593.

2CesaroneBelcaro G, Nicolaides AN et al. (2000) San Valentino epidemiologic vascular project. Angiology 51: S65-S68.

3Taitt HE (2018) Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Men's Health 6: 1807-1823.

4Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer NEJM 366-381.

5Velcheti V, Karink S, Bardot SF, Pralash ON (2008) Pathogenesis of prostate cancer: lessons from basic research. Ochsner J 4: 213-218.

6Mustafa M, Salih AF, Illzam EM, et al. (2016) Prostate cancer: pathophysiology, diagnosis, and prognosis. IOSR Journal of Dental and Med Sciences 15: 4-11.

7Rebbeck TR (2017) Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 27: 3-10.

8Hugosson J, Robol MJ, Mànsson M, et al. (2019) A 16-years follow-up of the European Randomized study of screening for prostate cancer. Eur Urol 76: 43-51.

9Gomella LG (2017) Prostate cancer statistics: anything you want them to be. Can J Urol 24: 8603-8604.

10Klein J, von demKnesebeck O (2015) Socioeconomic inequalities in prostate cancer survival: a review of the evidence and explanatory factors. Soc Sci Med 142: 9-18.

11Dasgupta P, Baade PD, Altken JF, et al. (2019) Geographical variations in prostate cancer outcomes: a systematic review of international evidence. Front Oncol 9: art 238.

12Roy S, Morgan SC (2019) Who dies from prostate cancer? An analysis of the surveillance epidemiology and end results database. Clin Oncol (R Coll Radiol) 31: 630-636.

13Robinson D, Garmo H, Lissbrant IF, et al. (2018) Prostate cancer death after radiotherapy or radical prostatectomy: a nationwide population-based observational study. Eur Urol 73: 502-511.

14Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78-83.

15Sutcliffe S, Giovannucci E, De Marzo AM, et. al. (2006) Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2160-2166.

16Caini S, Gandini S, Dudas M et al. (2014) Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 38: 329-338.

17(2018) Global Health Estimates (2016) death by Cause, Age, Sex, by Country and by Region 2000-2016. Geneva World Health Organization.

18Albert A and Harris E (1987) Multivariate interpretation of clinical laboratory data. Marcel Dekker, New York 1987.

19Allen D and Cady F (1982) Analyzing experimental data by regression. Wadwsworth.

20Besley, Kuh and WelshM (1980) Regression diagnostics. John Wiley & Sons.

21Cook D, and Weisberg S (1982) Residual and influence in regression. Chapman and Hall.

22Draper NR and Smith H (1966) Applied regression analysis. John Wiley & Sons.

23Cornelli U, Recchia M, Grossi E, Belcaro G (2018) Life expectancy does not depend on classical ecological variables: stochastic and nonstochastic analysis. GSL Public Health Epidemiol 1: 104-109.

24(2016) WHO guidelines for the treatment of Chlamydia trachomatis

25Al-Younes HM, Rdel T, Brinkmann V et al. (2001) Low iron availability modulates the course of Chlamydia pneumoniae infection. Cell Microbiol 3: 427-437.

26Barouch DH, Deeks SG (2014) Immunologic strategies for HIV-1 remission and eradication. Science 345: 169-174.

27Frosh AEP, Ayodo G, Odhiambo EO et al. (2018) Iron deficiency is prevalent among HIV-infected Kenian adults and is better measured by soluble transferrin receptor than ferritin. Am J Trop Med 99: 439-444.

28Haider BA, Spiegelman D, Hetzmark E et al. (2019) Anemia, iron deficiency, and iron supplementation in relation to mortality among HIV-infected patients receiving highly active antiretroviral therapy in Tanzania. Am J Trp Med Hyg 100: 1512-1520.

29Stelle I, Kalea AZ, Pereira DIA (2019) Iron deficiency anemia: experiences and challenges. Proc Nutr Soc 78: 19-26.

30Strum SB, McDermed JE, Scholz MC et al. (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79: 933- 941.

31Curtis KK, Adam TJ, Chen SC et al. (2008) Anaemia following initiation of androgen deprivation therapy for metastatic cancer: a retrospective chart review. Aging Male 11: 157-161.

32Ahmadi H, Daneshmand S (2003) Androgen deprivation therapy: evidence-based management of side effects. BJU international 111: 543-458.

33Higano CS (2003) Side effects on androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61: 32-38.

34Hicks BM, Lill-Dori AJ, Yin H, et al. (2017) Androgen deprivation therapy and risk of anemia in men with prostate cancer. Epidemiology 28: 712-718.

35Owen PJ, Daly RM, Liningston PM, Fraser SF (2017) Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer and Prostatic Diseases 20: 137-145.

36Nalesnik JG, Mysliwiech AG, Camby-Hagino E (2004) Anemiain men with advanced prostate cancer: incidence, etiology, and treatment. Rev Urol 6: 1-4.

37Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L (2016) Lancet 387: 907-916.

38Keusch GT (1990) Micronutrients and susceptibility to infection. Ann N Y Acad Sci 587: 181-188.

39Chandra RK, Au B, Woodford G, Hyam P (1976) Ciba Found Symp 51: 249-268.

40Weinberg ED (1974) Iron and susceptibility to infectious disease Science 184: 952-956.

41Ganzoni AM, Puschmann (1978) Iron deficiency in infection. Haematol Blood Transfus 21: 95-104.

42Ganz T (2018) Iron in infection. Int J Hematol 107: 7-15.

43Moore RD, Keruly JC, Chairsson RE (1999) Anemia and survival in HIV infections. J Acquir Immune Defic Syndr 19: 29-33.

44Weinberg ED (1996) The role of iron in cancer. Eur J Cancer Prev 5: 19-36.